Photo provided by EssilorLuxottica
Meet Essilor® Stellest® lenses, the first and only FDA market authorized spectacle lens to slow myopia progression in children*1. Click here to gain insights from EssilorLuxottica’s Monica Jong, BOptom, PhD, FAAO, FBCLA, Head of Medical Affairs, North America, about the introduction of Essilor Stellest lenses in the U.S., and how this innovation is poised to advance myopia management for children. Plus gain access to Essilor Stellest webinars tailored to optometrists, opticians and staff.
*Compared to single vision lenses. Results from a prospective, randomized, double-masked, multicenter U.S. clinical trial in myopic children aged 6–12 years at initiation of treatment.
1.Essilor International, data on file (2025)
